Last reviewed · How we verify

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid

University of Cape Town · Phase 3 active Small molecule

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid is a Anti-tuberculosis agent (fixed-dose combination) Small molecule drug developed by University of Cape Town. It is currently in Phase 3 development for Tuberculosis (drug-susceptible, pulmonary and extrapulmonary). Also known as: Rifafour.

This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis.

This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis. Used for Tuberculosis (drug-susceptible, pulmonary and extrapulmonary).

At a glance

Generic nameRifampicin, Pyrazinamide, Ethambutol and Isoniazid
Also known asRifafour
SponsorUniversity of Cape Town
Drug classAnti-tuberculosis agent (fixed-dose combination)
TargetBacterial RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid), cellular metabolism (pyrazinamide), arabinosyl transferase (ethambutol)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Rifampicin inhibits bacterial RNA polymerase, isoniazid inhibits mycolic acid synthesis in the cell wall, pyrazinamide disrupts cellular metabolism and energy production, and ethambutol inhibits arabinosyl transferases involved in cell wall synthesis. Together, these agents target multiple pathways to prevent resistance and achieve rapid bactericidal activity against tuberculosis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rifampicin, Pyrazinamide, Ethambutol and Isoniazid

What is Rifampicin, Pyrazinamide, Ethambutol and Isoniazid?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid is a Anti-tuberculosis agent (fixed-dose combination) drug developed by University of Cape Town, indicated for Tuberculosis (drug-susceptible, pulmonary and extrapulmonary).

How does Rifampicin, Pyrazinamide, Ethambutol and Isoniazid work?

This is a fixed-dose combination of four first-line anti-tuberculosis drugs that work synergistically to inhibit bacterial cell wall synthesis and protein production, killing Mycobacterium tuberculosis.

What is Rifampicin, Pyrazinamide, Ethambutol and Isoniazid used for?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid is indicated for Tuberculosis (drug-susceptible, pulmonary and extrapulmonary).

Who makes Rifampicin, Pyrazinamide, Ethambutol and Isoniazid?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid is developed by University of Cape Town (see full University of Cape Town pipeline at /company/university-of-cape-town).

Is Rifampicin, Pyrazinamide, Ethambutol and Isoniazid also known as anything else?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid is also known as Rifafour.

What drug class is Rifampicin, Pyrazinamide, Ethambutol and Isoniazid in?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid belongs to the Anti-tuberculosis agent (fixed-dose combination) class. See all Anti-tuberculosis agent (fixed-dose combination) drugs at /class/anti-tuberculosis-agent-fixed-dose-combination.

What development phase is Rifampicin, Pyrazinamide, Ethambutol and Isoniazid in?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid is in Phase 3.

What are the side effects of Rifampicin, Pyrazinamide, Ethambutol and Isoniazid?

Common side effects of Rifampicin, Pyrazinamide, Ethambutol and Isoniazid include Hepatotoxicity, Peripheral neuropathy, Hyperuricemia, Optic neuritis (ethambutol-related), Gastrointestinal disturbance, Rash.

What does Rifampicin, Pyrazinamide, Ethambutol and Isoniazid target?

Rifampicin, Pyrazinamide, Ethambutol and Isoniazid targets Bacterial RNA polymerase (rifampicin), mycolic acid synthesis (isoniazid), cellular metabolism (pyrazinamide), arabinosyl transferase (ethambutol) and is a Anti-tuberculosis agent (fixed-dose combination).

Related